Key result
Background insulin monotherapy is linked to ~18% higher risk of HHF or CV death in T2D.
Why the study?
Does canagliflozin reduce the risk of heart failure and cardiovascular events in patients with type 2 diabetes and high cardiovascular risk treated with background insulin monotherapy?
Cohort (n=14,530)
Randomized (underlying trials)
Does canagliflozin reduce the risk of heart failure and cardiovascular events in patients with type 2 diabetes and high cardiovascular risk treated with background insulin monotherapy?
Answers are grounded in this paper and cite their sources.
In patients with type 2 diabetes and high cardiovascular risk, background insulin monotherapy is an independent risk factor for heart failure and cardiovascular events, which can be effectively mitigated by the addition of canagliflozin.
Background/Introduction The impact of insulin on cardiorenal outcomes in type 2 diabetes (T2D) remains unclear among anti-diabetic treatments, while the proposed cardiovascular (CV) benefits of metformin are not well established. Additionally, although canagliflozin is known to lower cardiorenal risk, its specific effects in insulin-treated patients are not yet fully understood. Purpose This study aimed to evaluate the impact of background insulin and metformin monotherapy on major CV and renal outcomes in individuals with T2D and high CV risk, and to assess whether canagliflozin can offset the cardio-renal risk associated with different anti-diabetic therapies. Methods We merged data from the CANVAS and CREDENCE trials, totalling 14,530 participants aged 30–90 years, randomised to placebo or canagliflozin (100-300 mg) treatment and followed up for a median of 2.6 years. Among them, 2,766 (19%) were on insulin monotherapy and 2,127 (14.6%) on metformin monotherapy. Outcomes included a composite of hospitalisation for heart failure (hHF) and CV death (cvDeath), major adverse cardiovascular events (MACE), all-cause death (acDeath), non-fatal myocardial infarction (nfMI), and a composite of renal outcomes. Multivariable Cox proportional hazards models were used to assess risk, with extensive adjustments for confounders. Results Patients on insulin monotherapy were older, with longer diabetes duration and poorer glycaemic control. In univariate analysis, insulin was associated with an increased risk of hHF/cvDeath (HR=1.80 [95% CI:1.57-2.05]), MACE (HR=1.61 [95% CI:1.43-1.81]), acDeath (HR=1.66 [95% CI:1.45-1.90]), nfMI (HR=1.42 [95% CI:1.16-1.73]) and renal outcomes (HR=1.85 [95% CI:1.56-2.20]). After adjusting for confounders, insulin remained a risk factor only for hHF/cvDeath (HR=1.18 [95% CI:1.02-1.36]) and MACE (HR=1.22 [95% CI:1.02-1.45]). In contrast, metformin monotherapy was associated with a reduction in risk of hHF/cvDeath (HR=0.73 [95% CI:0.60-0.89]) MACE (HR=0.77 [95% CI:0.66-0.90]), acDeath (HR=0.78 [95% CI:0.64-0.94]) and renal outcomes (HR=0.71 [95% CI:0.55-0.91]), which disappeared after adjustment for all outcomes. At multivariable analysis, the treatment with canagliflozin significantly reduced the increased risk for hHF/cvDeath and MACE found in patients treated with insulin monotherapy. Conclusions In T2D patients with high CV risk, insulin monotherapy—but not metformin monotherapy—is associated with a higher risk of HF and CV events, independently of key clinical and biochemical characteristics, suggesting a direct effect rather than merely reflecting the clinical phenotype. Canagliflozin treatment effectively mitigates the elevated HF and CV risk linked to insulin therapy.
No takes yet. Share an insight, caveat, or question.
Chiriacò et al. (2025) conducted a cohort in Type 2 diabetes and high cardiovascular risk (n=14,530). Background insulin monotherapy vs. No insulin monotherapy was evaluated on Composite of hospitalisation for heart failure (hHF) and cardiovascular death (cvDeath) (HR 1.18, 95% CI 1.02-1.36). In patients with type 2 diabetes and high cardiovascular risk, background insulin monotherapy was independently associated with an increased risk of heart failure hospitalization or cardiovascular death.
Synapse has enriched 10 related papers. Consider them for comparative context: